support@mellalta.com   +1 (304) 306-0723

Digitally Optimised triple-combination asthma therapy-Latest CHMP opinion to watch

The Committee for Medicinal Products for Human Use (CHMP) supports Novartis‘ Enerzair Breezhaler, the first triple-combination asthma therapy that includes an optional digital sensor. Enerzair (formerly QVM149) consists of long-acting beta-agonist indacaterol (LABA), long-acting muscarinic […]

Read More

Get In Touch

Let's keep the conversation going